BILOPAQUE
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BILOPAQUE is an oral capsule diagnostic agent approved in 1969 by GE HealthCare, likely a contrast medium or imaging aid for gastrointestinal or biliary tract visualization. The specific mechanism of action and therapeutic class are not publicly documented in available data.
LOE Approaching
This legacy diagnostic product faces imminent loss of exclusivity, signaling a defensive, maintenance-focused commercial team focused on maximizing remaining patent life and operational efficiency.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BILOPAQUE careers are anchored in engineering, finance, and operations roles reflecting GE HealthCare's diagnostic device and imaging platform strategy rather than traditional pharmaceutical commercialization. Working on this legacy product offers exposure to global supply chain, cost management, and transition planning in a mature market.
Software EngineerFP&A intern
Worked on BILOPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.